Intellectual Property Prospector

IP Assets Owned by Firms in Transition

April 9, 2007
Volume 2, Number 15

Prospector Profiles in this Issue

(Click on Reference Number to go directly to Company Profile)

Company Name	Reference Number	Category Profile
NexMed, Inc.	**07.0492**	Audit Concerns
NextPhase Wireless, Inc.	**07.0493**	Loss/Deficit
Paincare Holdings, Inc.	**07.0494**	Audit Concerns
Point Therapeutics, Inc.	**07.0495**	Audit Concerns
RNS Software, Inc.	**07.0496**	Audit Concerns
Siga Technologies, Inc.	**07.0497**	Loss/Deficit
SpatiaLight, Incorporated	**07.0498**	Audit Concerns
SunCom Wireless Holdings, Inc.	**07.0499**	Loss/Deficit
Taro Pharmaceutical Industries Ltd.	**07.0500**	Audit Concerns
Visiphor Corporation	**07.0501**	Audit Concerns
Wave Systems Corporation	**07.0502**	Audit Concerns

(Click on Reference Number to go directly to Company Profile)

Intellectual Property Prospector identifies companies with total assets of any size filing for bankruptcy or reporting other financial difficulty and profiles their ownership of intellectual property. The Prospector features companies that meet strictly defined, predetermined criteria and is designed to support the efforts of firms and individuals interested in identifying opportunities in the specific area of intellectual property, which includes patents, trademarks, trade secrets, and licenses, among others. Information is compiled weekly and the Prospector is distributed by email every Sunday evening to arrive before 9:00AM every Monday. The Prospector is published by Beard Group, Inc. (http://BeardGroup.com). For subscription information call Customer Service at 240-629-3300, ext. 27.

Prospector Profile Selection Criteria:

In order to appear in the **Intellectual Property Prospector**, a company must report ownership of intellectual property assets, as well as one of the conditions listed below:

- An event which indicates financial distress; e.g., default, distressed exchange offer, preferred dividend omission, debt at deep discount, restructuring, low rating, audit concerns, covenant problems, and loss/deficit.

- Chapter 11, 7, or 15 bankruptcy filing

- Section 363 Sales

DISCLAIMER: The conditions for inclusion in the Prospector are selected by the editors, because, in their opinion, the occurrence of such an event or the existence of such a circumstance is a likely indicator of current or prospective financial or operating difficulty. There are, however, other reasons why such facts or circumstances may exist. The inclusion of a profile suggests the possibility of financial distress or the possibility that the company may be of interest to firms and individuals interested in identifying intellectual property for some other reason. *Inclusion should not be construed to represent analysis of the condition of the company or its intellectual property or a definitive determination that the company is in difficulty.*

ACCURACY & COVERAGE: The information contained herein is obtained from sources believed to be reliable. However, the accuracy of most data cannot be verified prior to publication, and the information is not guaranteed. Desired information is often incomplete, inaccurate, delayed or unavailable. Do not rely on the Prospector without independent verification.

SUBSCRIPTIONS: Subscription rate: $575 for six months, payable in advance. All subscriptions entered are continued until canceled. For subscription information call Customer Service at (240) 629-3300, ext. 27.

Intellectual Property Prospector is a publication **of Beard Group, Inc.**, P. O. Box 4250, Frederick, MD 21705, (240) 629-3300, http://www.beardgroup.com. ISSN 1935-3901. Publisher: Christopher Beard.

Prospector Profile 07.0465

Acusphere, Inc.

500 Arsenal Street
Watertown, MA 02472
(617) 648-8800

NAICS		541710
Employees		116
Revenue	(mil)	$0.00
Income	(mil)	($61.09)
Assets	(mil)	$94.82
Liability	(mil)	$36.37

(for the year ended 12/31/2006)

Category: Loss/Deficit

Event: Acusphere, Inc. reported a net loss of $61.089 million for fiscal year 2006, much higher than the net loss reported of $44.625 million in 2005 and $29.959 million in 2004. As a result of its recurring losses, the Company has an accumulated deficit of $281.141 million as of December 31, 2006. The Company also used cash for operating activities of $48.089 million in fiscal year 2006, compared to $30.682 million in 2005 and $19.318 million in 2004.

Intellectual Property: The Company's patents include internally developed patents as well as patents acquired from third parties. As of March 2007, the Company owned 31 issued U.S. patents, one allowed U.S. patent and 20 U.S. patent applications. Six of the issued U.S. patents are directed to aspects of the spray drying method for manufacturing microparticles. Four issued U.S. patents and eight U.S. patent applications are related to various aspects of its porous microparticle delivery technology. Five issued U.S. patents relate to aspects delivery of hydrophobic drugs, including AI-850. The Company also owns a number of pending international and foreign patent applications corresponding to these U.S. patents and applications. [SEC Filing 10-K 03-16-07]

Description: The Company develops new drugs and formulations of existing drugs using its proprietary porous microparticle technology in the United States.

Officers: Sherri C. Oberg (Pres., CEO & Dir.); John F. Thero (SVP & CFO); Frank Baldino, Jr. (Dir.); Garen Bohlin (Dir.); Martyn Greenacre (Dir.); Sandra L. Fenwick (Dir.); Derek Lemke-von Ammon (Dir.)

Auditor: Deloitte & Touche LLP

Securities: Common Stock-Symbol ACUS; NasdaqCM;
38,101,913 common shares outstanding as of March 2, 2007.

Return to top

Prospector Profile 07.0466

Advanstar Communications, Inc.

641 Lexington Avenue
New York, NY 10022
(212) 951-6600

NAICS		561000
Employees		1,000
Revenue	(mil)	$323.72
Income	(mil)	($41.69)
Assets	(mil)	$739.97
Liability	(mil)	$636.72

(for the year ended 12/31/2006)

Category: Low Rating

Event: Moody's Investors Service placed its 'Caa1' rating of Advanstar Communications, Inc.'s 12% senior subordinated global notes under review for possible downgrade. The rating review follows the report that the Company has agreed to be acquired by an investor group led by Veronis Suhler Stevenson in a $1.1- billion transaction. Moody's said the review for possible downgrade will consider the terms and conditions of the proposed acquisition, the review of the funding in the proposed acquisition, the anticipated impact that the acquisition will have on the Company's financial and operating profile, and the strategic merits of the acquisition.

Intellectual Property: The Company considers trademarks, trade names, service marks, copyrights, trade secrets and similar intellectual property as important to its success. The Company relies on trademark, service mark, copyright and trade secret laws, as well as licensing and confidentiality agreements, to protect intellectual property rights. The Company generally registers material trademarks and service marks in the United States and in certain other key countries in which these trademarks and service marks are used. [SEC Filing 10-K 04-02-07]

Description: The Company provides integrated marketing solutions for the fashion and licensing, powersports, and life sciences industries.

Officers: James M. Alic (Chair & VP); Joseph Loggia (CEO & Dir.); Eric I. Lisman (EVP); Laura McConnell (EVP); Daniel M. Phillips (EVP); Theodore S. Alpert (VP-Finance & CFO); R. Steven Morris (VP); Rick Teese (VP & Chief Technology Officer); Oh Sang Kwon (Dir.); Douglas B. Fox (Dir.); Charles Pieper (Dir.); Kamil Salame (Dir.); Scott Marden (Dir.)

Auditor: PricewaterhouseCoopers LLP

Securities: 1,000,000 common shares outstanding as of April 2, 2007.
10.75% second priority senior secured notes due 2010; 12% senior subordinated notes due 2011.

Notes: There is no public trading market for the Company's common stock.

Return to top

Prospector Profile 07.0467

American Media Operations, Inc.
1000 American Media Way
Boca Raton, FL 33464
(561) 997-7733

NAICS		511120
Employees		1,421
Revenue	(mil)	$496.17
Income	(mil)	($160.89)
Assets	(mil)	$1,289.31
Liability	(mil)	$1,279.99

(for the year ended 3/31/2006)

Category: Loss/Deficit

Event: American Media Operations, Inc. reported that for the year ended March 31, 2006, it had a net loss of $160.9 million on total operating revenues of $496.2 million, as compared with a net loss of $13.8 million on total operating revenues of $501.8 million for the year ended March 31, 2005. As of March 31, 2006, the Company's balance sheet showed total assets of $1.29 billion and total liabilities of $1.28 billion, resulting to total stockholders' equity of $9.32 million. The Company's balance sheet as of March 31, 2006, also showed strained liquidity with total current assets of $124.8 million available to pay total current liabilities of $163.6 million. Accumulated deficit as of March 31, 2006, was $272.5 million, as compared with $111.6 million a year earlier.

Intellectual Property: The Company entered into a trademark license agreement with Weider Health and Fitness for the exclusive right to use the Weider trademarks on the cover and in the editorial content of existing Weider titles and in any future healthy living or fitness-related publications in any media. The Company was also given the non-exclusive right to use the trade name Joe Weider on products and services other than publications. It also has the right to use the Weider, Team Weider and Joe Weider trademarks in most other countries in the world. In April 2005, the Company licensed certain trademarks related to the Mr. Olympia fitness events to Mr. Olympia LLC. [SEC Filing 10-K 03-23-07]

Description: The Company's principal activity is to publish general interest magazines.

Officers: David J. Pecker (Chair & CEO); John J. Miller (Pres. & COO); Michael B. Kahane (EVP, Sec. & Gen. Counsel); John F. Craven (EVP & CFO); Austin M. Beutner (Dir.); Jeff Sagansky (Dir.); Anthony J. DiNovi (Dir.); Soren L. Oberg (Dir.); Michael Garin (Dir.); Saul D. Goodman (Dir.); Richard Bressler (Dir.); Daniel G. Ross (Dir.)

Auditor: Deloitte & Touche LLP

Securities: 7,507.6 common shares outstanding as of February 28, 2007.

Return to top

Prospector Profile 07.0468

Auriga Laboratories, Inc.
2029 Century Park East, Suite 1130
Los Angeles, CA 90067
(678) 282-1600

NAICS		325412
Employees		24
Revenue	(mil)	$3.17
Income	(mil)	($11.71)
Assets	(mil)	$10.60
Liability	(mil)	$7.04

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Williams & Webster PS raised substantial doubt about Auriga Laboratories Inc.'s ability to continue as a going concern after auditing the Company's consolidated financial statements for the period April 1, 2006 to ended December 31, 2006. The auditor pointed to the Company's sustained substantial operating losses since inception, negative working capital, and limited cash resources.

Intellectual Property: The Company has applied for a registration of "Auriga Laboratories" as a trademark in the United States. In addition, it has applied for registrations of "Auriga Development," "Auriga Pharmaceuticals" and "Stesso Pharmaceuticals" as trademarks in the US. The Company has been licensed rights to use the trademarks Extendryl® and Levall® from their respective owners. In addition, it also has filed US trademark applications for the trademarks Akurza™, Zinx™, Xyralid™, Aquoral™, Dura-Vent™, Orchestrated Therapy™, The Doctor Recommended Zinc™, Innovation in Oral Hydration™ and Our Business is Your Health™. The Company has obtained, and expect to continue to seek, licenses to patents and patent applications and other proprietary rights from others. The Company has six patent applications or provisional patent applications pending in the US Patent and Trademark Office and plans to use Patent Cooperation Treaty filings in an attempt to expand coverage of the pending US patent applications. [SEC Filing 10-K 03-30-07]

Description: The Company develops pharmaceutical products for the respiratory, dermatology and psychiatry markets. Its portfolio consists of Aquoral™, Zinx™, Akurza™, Xyralid™, Extendryl® and Levall® product lines.

Officers: Philip S. Pesin (Chair & CEO); Charles R. Bearchell (CFO); Andrew Shales (COO & Sec.); Alan Roberts (Chief Scientific Officer); Dayne Wagoner (Dir.); Brian P. Alleman (Dir.); Steve C. Glover (Dir.); Trevor K. Pokorney (Dir.)

Auditor: Williams & Webster PS

Securities: Common Stock Symbol ARGA.OB; OTC BB;
42,053,759 common shares outstanding as of March 12, 2007.

Return to top

Prospector Profile 07.0469

AVI Biopharma, Inc.

One SW Columbia Street, Suite 1105
Portland, OR 97258
(503) 227-0554

NAICS		541710
Employees		123
Revenue	(mil)	$0.12
Income	(mil)	($31.07)
Assets	(mil)	$40.86
Liability	(mil)	$3.15

(for the year ended 12/31/2006)

Category: Loss/Deficit

Event: AVI Biopharma, Inc. reported a net loss of $31,073,012 for the year ended December 31, 2006, higher than the net loss reported during the past two years of $16,675,864 in 2005 and $24,777,694 in 2004. As a result of its recurring losses, the Company has an accumulated deficit of $203,721,256 as of December 31, 2006.

Intellectual Property: The Company has developed or acquired a comprehensive body of intellectual rights. The Company's policy is to patent the technology, inventions, and improvements that are important to the development of its business and are patentable. It also depends upon trade secrets, know-how, and continuing technological innovation to develop and maintain competitive position. A patent estate including 202 patents issued or licensed, and 198 pending patent applications protects its technologies. The Company intends to protect proprietary technology with additional filings as appropriate. The Company has also acquired certain product/technology licenses from The Ohio State University and Dr. Vernon Stevens. These licenses include exclusive royalty-bearing licenses covering the composition, manufacturing and use of AVICINE in all fields of use, including treating and preventing cancer, with the exception of fertility regulation. The proprietary rights also include the unrestricted use of vaccine technology for non-hormonal cancer applications. [SEC Filing 10-K 03-16-07]

Description: The Company engages in the development of therapeutic products based on NEUGENE antisense technology.

Officers: Denis R. Burger, Ph.D. (Chair & CEO); Alan P. Timmins (Pres. & COO); Mark M. Webber (CFO & CIO); Jack L. Bowman (Dir.); Michael D. Casey (Dir.); John W. Fara, Ph.D (Dir.); K. Michael Forrest (Dir.); John C. Hodgman (Dir.); James B. Hicks, Ph.D. (Dir.)

Auditor: KPMG LLP

Securities: Common Stock-Symbol AVII; NasdaqGM;
53,282,841 common shares outstanding as of March 14, 2007.

Return to top

Prospector Profile 07.0470

Braintech, Inc.
#102 - 930 West 1st St.
North Vancouver, British Columbia V7P 3N4
Canada
(604) 988-6440

NAICS		541710
Employees		19
Revenue	(mil)	$1.76
Income	(mil)	($5.96)
Assets	(mil)	$1.33
Liability	(mil)	$3.39

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Smythe Ratcliffe LLP raised substantial doubt about Braintech, Inc.'s ability to continue as a going concern citing recurring losses from operations after auditing the Company's financial statements as of Dec. 31, 2006, and 2005. The Company had a net loss of $6 million on sales of $1.8 million for the year ended Dec. 31, 2006, as compared with a net loss of $2.7 million on sales of $1.2 million for the year ended Dec. 31, 2005.

Intellectual Property: The Company has registered the trademarks "Braintech" "eVF" and "eVisionFactory" and has applied for registration of the trademark "SC3D" with the US Patent and Trademark Office. The Company has registered the trademarks "SC3D", "eVF", and "eVisionFactory" in Canada. On January 31, 2002, the Company filed an application in Canada regarding the method and apparatus for single camera 3D vision guided robotics and has filed identical applications with the US Patent Office, Patent Cooperation Treaty and the Japanese Patent Office. On July 14, 2004, the Company filed an application in the US Patent Office regarding the method and apparatus for multi camera surround 3D vision guided robotics. [SEC Filing 10-K 03-26-07]

Description: The Company is engaged in the development, supply and support of machine vision guidance systems for robots used in manufacturing industries. The field of vision guided robotics requires its vision systems to incorporate advanced robotic engineering and programming know-how for optimal integration with the robotic systems.

Officers: Owen L.J. Jones (CEO & Dir.); Babak Habibi (Pres., COO & Dir.); Edward A. White (CFO, Sec., Treas. & Dir.); James L. Speros (Dir.); Drew Miller (Dir.); Clifford G. Butler (Dir.)

Auditor: Smythe Ratcliffe LLP

Securities: Common Stock-Symbol BRHI.OB; OTC BB;
33,532,433 common shares outstanding as of March 22, 2007.

Return to top

Prospector Profile 07.0471

Celsia Technologies, Inc.

1395 Brickell Avenue
Miami, FL 33131
(305) 529-6290

NAICS		334513
Employees		36
Revenue	(mil)	$0.10
Income	(mil)	($6.77)
Assets	(mil)	$2.04
Liability	(mil)	$2.28

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: PKF raised substantial doubt about Celsia Technologies Inc.'s ability to continue as a going concern after auditing the Company's consolidated financial statements for the year ended Dec. 31, 2006. The auditing firm reported that at Dec. 31, 2006, the Company has limited revenue-producing operations and has an accumulated deficit of $23.7 million.

Intellectual Property: The Company has been granted patents relating to its iCurie Cooled® technology in the United States, Korea, Japan, China, Russia, and Taiwan. In addition, the Company currently has pending patent applications relating to the iCurie Cooled® technology in Singapore, Brazil, India, and the 17 member countries of the European Union. The Nano Spreader Technology™ (NST) is protected by several pending Company patents. The Iceon 1000C Desktop CPU cooler incorporates Celsia's patented technology to form the highest performance cooler in its class on the market today. The Iceon 1000C and its components are covered by multiple pending patents. The Company's Iceon 1000CG is similar to the Iceon 1000C, based on Celsia's patented Nano spreader technology, and gives the user performance and sound level advantages. [SEC Filing 10-KSB 03-27-07]

Description: The Company engages in the research and development of cooling solutions for the personal computer, flat panel display, and the light emitting diode-lighting industries.

Officers: Hakan Wretsell (Pres., CEO & Dir.); Michael Karpheden (Sec., COO & CFO); Dr. Jeong-Hyun Lee (CTO & Dir.); Alan B. Miller (Dir.); David H. Clarke (Dir.); Peter Rugg (Dir.); Gregory J. Osborn (Dir.)

Auditor: PKF

Securities: Common Stock-Symbol CSAT.OB; OTC BB;
36,382,038 common shares outstanding as of March 14, 2007.

Return to top

Prospector Profile 07.0472

CenterStaging Corporation

3407 Winona Avenue
Burbank, CA 91504
(818) 559-4333

NAICS		711130
Employees		99
Revenue	(mil)	$5.71
Income	(mil)	($25.30)
Assets	(mil)	$7.39
Liability	(mil)	$12.68

(for the year ended 6/30/2006)

Category: Loss/Deficit

Event: CenterStaging Corp.'s balance sheet at Dec. 31, 2006, showed $6,973,041 in total assets, $16,021,743 in total liabilities, and $604,662 in minority interests, resulting in a $9,653,364 stockholders' deficit. The Company's Dec. 31 balance sheet also showed strained liquidity with $878,715 in total current assets available to pay $9,813,219 in total current liabilities. For the second quarter ended Dec. 31, 2006, the Company reported a $3,743,876 net loss on $1,741,626 of revenues, compared with a $2,801,037 net loss on $1,559,792 of revenues in the same period last year.

Intellectual Property: The Company regards its intellectual property, particularly copyrights, trademarks and trade secrets, and rights to original content under rehearsals.com, to be of considerable value and importance to its business and success. The Company relies on a combination of trademark, and trade secrecy laws, confidentiality procedures and contractual provisions to protect intellectual property rights. [SEC Filing 10-KSB 09-28-06]

Description: The Company provides musical production support and services for live musical performances at televised award shows and events in the United States.

Officers: Roger Paglia (Pres. & Dir.); Howard Livingston (CFO & Dir.); Johnny Caswell (Dir.); Jan Parent (Dir.)

Auditor: Stonefield Josephson

Securities: Common Stock-Symbol CNSC.OB; OTC BB;
61,784,995 common shares outstanding as of January 31, 2007.

Return to top

Prospector Profile 07.0473

Communication Intelligence Corporation

275 Shoreline Drive, Suite 500
Redwood Shores, CA 94065
(650) 802-7888

NAICS		334119
Employees		21
Revenue	(mil)	$2.34
Income	(mil)	($3.29)
Assets	(mil)	$6.13
Liability	(mil)	$2.54

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: GHP Horwath PC raised substantial doubt about Communication Intelligence Corporation's ability to continue as a going concern after auditing the company's financial statements as of Dec. 31, 2006. The auditing firm pointed to the Company's recurring losses and accumulated deficit. The Company incurred significant losses since its inception and at Dec. 31, 2006, accumulated deficit was about $87.8 million.

Intellectual Property: The Company relies on a combination of patents, copyrights, trademarks, trade secrets and contractual provisions to protect its software offerings and technologies. Over the years, the Company has developed and patented major elements of its software offerings and technologies. In addition, the Company acquired from PenOp, Inc. and its subsidiary, a significant patent portfolio relevant to the markets in which the Company sells its products. The Company currently has 10 patents registered with the US Patent and Trademark Office. The Company believes that these patents provide a competitive advantage in the electronic signature and biometric signature verification markets. The Company believes that for a significant period of time its patents will deter competitors from introducing competing products without creating substantially different technology or licensing or infringing its technology. The Company has an extensive list of registered and unregistered trademarks and applications in the United States and other countries. [SEC Filing 10-K 03-26-07]

Description: The Company is a leading supplier of electronic signature solutions for business process automation in the financial industry as well as the recognized leader in biometric signature verification.

Officers: Guido D. DiGregorio (Chair, Pres. & CEO); Francis V. Dane (CFO & Sec.); Russel L. Davis (VP & CTO); Louis P. Panetta (Dir.); C. B. Sung (Dir.); David E. Welch (Dir.)

Auditor: GHP Horwath PC

Securities: Common Stock-Symbol CICI.OB; OTC BB;
107,557,161 common shares outstanding as of March 22, 2007.

Return to top

Prospector Profile 07.0474

Constar International, Inc.

One Crown Way
Philadelphia, PA 19154
(215) 552-3700

NAICS		326100
Employees		1,839
Revenue	(mil)	$926.97
Income	(mil)	($12.02)
Assets	(mil)	$503.96
Liability	(mil)	$548.80

(for the year ended 12/31/2006)

Category: Loss/Deficit

Event: Constar International, Inc. posted a net loss of $12,022,000 on net sales of $926,969,000 for the year ended December 31, 2006, as compared with a net loss of $59,990,000 on revenues of $928,045,000 for the same period in 2005. The Company's balance sheet showed increased stockholders' deficit from $41,860,000 in 2005 to $44,839,000 in 2006 as well as increased accumulated deficit from $289,034,000 in 2005 to $301,056,000 in 2006.

Intellectual Property: The Company's portfolio of intellectual property assets includes U.S. and foreign utility and design patents and patent applications. Among these assets are a number of patents on its oxygen-scavenging technology, as well as patents related to its line of heat-set bottles. The Company's Oxbar technology is subject to a worldwide royalty-free cross-license with Rexam AB, which owns several patents relating to oxygen-scavenging technology. The cross-license agreement gives both parties the right to use and sublicense each other's oxygen-scavenging technology patents but not each other's know-how. Chevron Phillips Chemical Company LP holds a royalty-based, exclusive, worldwide license to the Oxbar patents, but not for rigid polyester packages such as PET containers. Constar has granted royalty-bearing licenses to some of its competitors for certain applications of the Oxbar patents. In addition, the Company is offering direct sales of Monoxbar™ materials. The Company relies on proprietary know-how, continuing technological innovation and other trade secrets to develop products and maintain its competitive position. [SEC Filing 10-K 03-29-07]

Description: The Company produces polyethylene terephthalate plastic containers for consumer products companies.

Officers: Michael J. Hoffman (Pres., CEO, & Dir.); Walter S. Sobon (EVP & CFO); James C. T. Bolton (SVP); L. William Secoy (SVP); Donald P. Deubel (VP); Frank E. Gregory (VP); Jerry A. Hatfield (VP); David J. Waksman (VP, Gen. Counsel, & Sec.)

Auditor: PricewaterhouseCoopers LLP

Securities: Common Stock Symbol CNST; NasdaqGM;
12,577,342 common shares outstanding as of March 21, 2007.

Return to top

Prospector Profile 07.0475

Counterpath Solutions, Inc.

8th Floor 100 West Pender Street
Vancouver, British Columbia V6B 1R8
Canada
(604) 320-3344

NAICS		541512
Employees		54
Revenue	(mil)	$4.62
Income	(mil)	($1.28)
Assets	(mil)	$3.26
Liability	(mil)	$2.86

(for the year ended 12/31/2006)

Category: Loss/Deficit

Event: Counterpath Solutions Inc. reported a net loss of $1,347,046 on total revenue of $1,007,582 for the third quarter ended Jan. 31, 2007, compared with a net loss of $428,942 on total revenue of $1,237,932 for the same period ended Jan. 31, 2006. The Company's balance sheet at Dec. 31, 2006, showed $4,834,927 in total assets and $4,867,658 in total liabilities, resulting in a $32,731 total stockholders' deficit. The Company also has an accumulated deficit of $4,377,426 at the end of 2006.

Intellectual Property: Other than third-party codecs (compression/decompression software used for compressing and decompressing the audio/voice and video data packets) and some special function libraries, which are either open-source or licensed from third parties, the Company owns 100% of the source code for its eyeBeam and X-Lite products. The Company has registered these domain names: www.counterpath.com; www.counterpath.ca; www.xten.com; www.xten.net; www.sipindex.com; www.xtunnels.org; www.videoblog.com; www.videoblog.net; and www.videoblog.info. The Company relies on trade secrets and trademarks to protect intellectual property. At the present, the Company does not have any patents. The Company has begun to articulate and document information regarding several proprietary processes and concepts with a view to filing and applying for patent protection in the next 12-month period. [SEC Filing 10-KSB 07-31-06]

Description: The Company focuses on the design, development and marketing of multimedia application software.

Officers: Mark Bruk (Chair, CEO, Sec. & Treas.); Donovan Jones (Pres. & COO); Jason Fischl (CTO); Larry Timlick (Dir.); Chris Cooper (Dir.)

Auditor: Amisano Hanson

Securities: Common Stock-Symbol CTPS.OB; OTC BB;
37,940,983 common shares outstanding as of March 9, 2007.

Return to top

Prospector Profile 07.0476

Digital Recorders, Inc.
5949 Sherry Lane, Suite 1050
Dallas, TX 75225
(214) 378-8992

NAICS		333315
Employees		198
Revenue	(mil)	$51.34
Income	(mil)	($3.89)
Assets	(mil)	$37.36
Liability	(mil)	$20.16

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: PricewaterhouseCoopers LLP raised substantial doubt about Digital Recorders Inc.'s ability to continue as a going concern after auditing the company's financial report at Dec. 31, 2006, and 2005. The auditing firm pointed to the company's recurring losses from operations and accumulated deficit. The company recorded a net loss of $3.9 million on net sales of $51.3 million for the year ended Dec. 31, 2006, as compared with a net loss of $5.9 million on net sales of $45.3 million for the year ended Dec. 31, 2005.

Intellectual Property: The Company currently owns two design patents and has a combination of copyrights, alliances, trade secrets, nondisclosure agreements, and licensing agreements to establish and protect ownership of, and access to, proprietary and intellectual property rights. Attempts to keep the results of research and development efforts proprietary may not be sufficient to prevent others from using some or all of such information or technology. The Company has registered DAC®, Digital Recorders®, Talking Bus®, TwinVision®, VacTelltm, Mobitec® trademarks, logos, slogans, taglines, and trade names with the U.S. Patent and Trademark Office and abroad. The Company intends to pursue new patents and other intellectual property rights protection methods covering technology and developments on an on-going basis. [SEC Filing 10-K 03-28-07]

Description: The Company, through its subsidiaries, engages in the design, manufacture, sale, and service of information technology and surveillance technology products worldwide.

Officers: David L. Turney (Chair, Pres. & CEO); Stephen P. Slay (VP, CFO, Treas. & Sec.); John D. Higgins (Dir.); Stephanie L. Pinson (Dir.); C. James Meese Jr. (Dir.); John K. Pirotte (Dir.); Juliann Tenney, J.D. (Dir.)

Auditor: PricewaterhouseCoopers LLP

Securities: Common Stock-Symbol TBUS; NasdaqCM;
10,062,055 common shares outstanding as of February 28, 2007.

Return to top

Prospector Profile 07.0477

Discovery Laboratories, Inc.

2600 Kelly Road, Suite 100
Warrington, PA 18976-3646
(215) 488-9300

NAICS		541710
Employees		100
Revenue	(mil)	$0.00
Income	(mil)	($46.33)
Assets	(mil)	$34.40
Liability	(mil)	$20.08

(for the year ended 12/31/2006)

Category: Loss/Deficit

Event: Discovery Laboratories, Inc. reported a net loss of $46.333 million for the fiscal year ended December 31, 2006, compared to $58.904 million in 2005 and $46.203 million in 2004. As a result, the Company reported an accumulated deficit of $248.298 million at December 31, 2006, higher than the the accumulated deficit of $201.965 million at December 31, 2005.

Intellectual Property: The Company's precision-engineered surfactant platform technology, including Surfaxin, is based on the proprietary peptide, sinapultide. The Company has received an exclusive, worldwide license and sublicense from Johnson & Johnson and The Scripps Research Institute for a series of over 30 patents and patent filings which are important to its strategy for commercializing precision-engineered surfactant technology for the diagnosis, prevention and treatment of disease. In May of 2005, the Company filed United States and International patent applications (US 11/130,783 and PCT US/2005/0178184) directed to systems, devices and methods for non-invasive pulmonary delivery of aerosolized surfactant. The Company also has seven patent applications pending with the US Patent and Trademark Office. [SEC Filing 10-K 03-16-07]

Description: The Company develops Surfactant Replacement Therapies for respiratory diseases.

Officers: Herbert H. McDade, Jr. (Chair)Robert J. Capetola, Ph.D. (Pres., CEO & Dir.); John G. Cooper (EVP & CFO); David L. Lopez, C.P.A., Esq. (EVP & Gen. Counsel); W. Thomas Amick (Dir.); Antonio Esteve, Ph.D. (Dir.); Marvin E. Rosenthale, Ph.D. (Dir.)

Auditor: Ernst & Young LLP

Securities: Common Stock-Symbol DSCO; NasdaqGM;
70,502,930 common shares outstanding as of March 8, 2007.

Return to top

Prospector Profile 07.0478

DOV Pharmaceutical, Inc.

Continental Plaza, 433 Hackensack Ave.
Hackensack, NJ 07601
(201) 968-0980

NAICS		325412
Employees		41
Revenue	(mil)	$25.95
Income	(mil)	($38.37)
Assets	(mil)	$50.36
Liability	(mil)	$80.00

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: PricewaterhouseCoopers LLP expressed substantial doubt about DOV Pharmaceutical Inc.'s ability to continue as a going concern after auditing the Company's financial statements for the years ended Dec. 31, 2006, and 2005. The auditing firm pointed to the Company's recurring losses from operations and net capital deficiency.

Intellectual Property: The Company owns 12 issued U.S. patents that are in force as of December 31, 2006. In 2006, a U.S. patent was awarded covering a novel polymorphic form of bicifadine. The Company filed U.S. patent applications claiming novel sustained release formulations of bicifadine, methods for sustained release delivery of bicifadine to treat pain, and therapeutic methods employing bicifadine to treat chronic pain. In 2005, the Company filed a U.S. provisional application employing bicifadine to treat neuropathic disorders and the use of bicifadine for controlling fever and menopausal symptoms. In 2005, the Company filed a U.S. provisional patent application directed to therapeutic uses, compositions and methods employing bicifadine to treat urological disorders. In 2006, the Company filed a U.S. provisional patent application directed to novel salts and co-crystals of pyrazolopyrimidines, including indiplon and ocinaplon. In April 2002, a U.S. patent was issued for DOV 21,947, a triple uptake inhibitor under development for the treatment of depression. Between 2003 and 2006, five patents have issued covering DOV 102,677 for the treatment of indications including alcohol abuse, alcoholism, Parkinson’s disease, restless leg syndrome, and attention deficit disorder. [SEC Filing 10-K 03-30-07]

Description: The Company is focused on the discovery, in-licensing, development and commercialization of novel drug candidates.

Officers: Arnold S. Lippa (Chair); Barbara G. Duncan (CEO, Treas. & Dir.); Warren Stern (SVP); Zola Horovitz (Dir.); Patrick Ashe (Dir.); Daniel S. Van Riper (Dir.); Theresa A. Bischoff (Dir.); Dennis G. Podlesak (Dir.)

Auditor: PricewaterhouseCoopers LLP

Securities: Common Stock-Symbol DOVP.PK; PNK;
26,743,657 common shares outstanding as of March 15, 2007.

Return to top

Prospector Profile 07.0479

Eddie Bauer Holdings, Inc.
15010 North East 36th Street
Redmond, WA 98052
(425) 755-6544

NAICS		422320
Employees		2,457
Revenue	(mil)	$1,013.45
Income	(mil)	($211.98)
Assets	(mil)	$855.91
Liability	(mil)	$509.27

(for the year ended 12/30/2006)

Category: Audit Concerns

Event: BDO Seidman LLP raised substantial doubt about Eddie Bauer Holdings Inc.'s ability to continue as a going concern after auditing the Company's financial statements for the years ended Dec. 31, 2006, and 2005. The auditing firm pointed to the Company's ability to refinance its term loan to avoid an event of default related to the failure of the Company in meeting its financial covenants in one or more future interim periods.

Intellectual Property: As of December 30, 2006, the Company had over 80 trademark registrations and pending trademark applications in the U.S. and over 275 registered trademarks and 30 pending trademark applications in foreign countries. The trademarks include Eddie Bauer®, EBTek®, Eddie Bauer Adventurer®, the Eddie Bauer signature logo, the Eddie Bauer goose logo and various other marks used in its business. The Company regards the trademarks as key assets and believe they have substantial value in the marketing of its products. The Company also grants licenses to other parties to manufacture and sell certain products with its trademarks. [SEC Filing 10-K 03-29-07]

Description: The Company, through its subsidiaries, operates as a specialty retailer that sells casual sportswear and accessories in the United States and Canada.

Officers: William T. End (Chair); Kathleen Boyer (SVP); Shelley Milano (SVP, Sec. & Gen. Counsel); Ann Perinchief (SVP); Howard Gross (Int. CEO & Dir.); John C. Brouillard (Dir.); Paul E. Kirincic (Dir.); Kenneth M. Reiss (Dir.); Laurie M. Shahon (Dir.); Edward M. Straw (Dir.); Stephen E. Watson (Dir.)

Auditor: BDO Seidman LLP

Securities: Common Stock-Symbol EBHI; NasdaqGM;
30,309,931 common shares outstanding as of March 28, 2007.

Return to top

Prospector Profile 07.0480

enherent Corp.

101 Eisenhower Parkway, Suite 300
Roseland, NJ 07068
(212) 889-7722

NAICS		541512
Employees		272
Revenue	(mil)	$30.12
Income	(mil)	($0.30)
Assets	(mil)	$10.04
Liability	(mil)	$11.06

(for the year ended 12/31/2006)

Category: Loss/Deficit

Event: enherent Corp. posted a net loss of $297,509 on revenues of $30,120,188 for the year ended December 31, 2006, as compared with a net loss of $743,505 on revenues of $27,320,643 for the same period in 2005. As of December 31, 2006, the Company's balance sheet showed strained liquidity with $5,086,844 in total current assets and $7,823,032 in total current liabilities. The Company also reported $1,019,400 in stockholders' deficit and $28,326,650 in accumulated deficit.

Intellectual Property: The Company presently holds no patents or registered copyrights, but has several registered trademarks for "enherent" and the enherent logo and several registered trademarks for "Dynax" and the Dynax logo. In addition, the Company currently relies on unregistered copyrights, trade secrets and unpatented proprietary know-how in the operation of its business. The Company employs various methods, including non-disclosure agreements and other contractual arrangements with employees and suppliers and technical protective measures to protect its proprietary know-how. [SEC Filing 10-K 03-29-07]

Description: The Company provides information technology services that include IT consultative resource and staffing, systems integration, and application development.

Officers: Pamela Fredette (Chair, Pres., & CEO); Karl Brenza (CFO); Lori Stanley (VP-HR, Gen. Counsel, & Sec.); Bill O'Brien (VP-Recruiting); Bruce Morgan (VP-Sales); Kevin Jinks (Chief Business Dev't. Officer); Douglas K. Mellinger (Dir.); Thomas Minerva (Dir.); Faith Griffin (Dir.); William Cary (Dir.)

Auditor: Cornick, Garber & Sandler LLP

Securities: Common Stock Symbol ENHT.OB; OTC BB;
50,661,451 common shares outstanding as of March 09, 2007.

Return to top

Prospector Profile 07.0481

eTwine Holdings, Inc.

366 North Broadway, Suite 41042
Jericho, NY 11753
(516) 942-2030

NAICS		516110
Employees		1
Revenue	(mil)	$0.09
Income	(mil)	($0.59)
Assets	(mil)	$0.24
Liability	(mil)	$0.11

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Webb & Company PA raised substantial doubt about eTwine Holdings, Inc.'s ability to continue as a going concern due to its accumulated deficit of $704,544 and negative cash flow from operations of $194,795 since inception.

Intellectual Property: In November 2006, the Company launched an online dating website located at http://www.IamFreeTonight.com. IamFreeTonight.com offers several unique features for singles and utilizes the latest technologies to give singles an enhanced user experience compared to other online dating sites currently on the market. [SEC Filing 10-KSB 03-16-07]

Description: The Company, through its wholly owned subsidiary, eTwine, Inc., engages in the ownership and operation of an online dating and social community Web site.

Officers: Clifford Lerner (Chair, Pres., CEO & CFO)

Auditor: Webb & Company PA

Securities: Common Stock-Symbol ETWI.OB; OTC BB;
9,028,780 common shares outstanding as of March 16, 2007.

Return to top

Prospector Profile 07.0482

Format, Inc.
27126 Paseo Espada, Suite 705
San Juan Capistrano, CA 92675
(949) 481-9203

NAICS		516110
Employees		1
Revenue	(mil)	$0.08
Income	(mil)	($0.11)
Assets	(mil)	$0.09
Liability	(mil)	$0.14

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Michael Pollack CPA expressed substantial doubt on Format, Inc.'s ability to continue as a going concern after auditing the Company's financial statements. The Company has sustained operating losses over the past few years and has sustained cash flow shortages that was funded by an officer of the Company.

Intellectual Property: The Company owns the Internet domain name "www.formatds.com". Under current domain name registration practices, no one else can obtain an identical domain name, but someone might obtain a similar name, or the identical name with a different suffix, such as ".org", or with a country designation. [SEC Filing 10-KSB 03-16-07]

Description: The Company provides EDGARizing services to various commercial and corporate entities.

Officers: Ryan A. Neely (Pres., CFO, Sec. & Dir.); Robert D. Summers (Dir.)

Auditor: Michael Pollack CPA

Return to top

Prospector Profile 07.0483

GVI Security Solutions, Inc.

2801 Trade Center Drive, Suite 120
Carrollton, TX 75007
(972) 245-7353

NAICS		561621
Employees		42
Revenue	(mil)	$43.97
Income	(mil)	($16.49)
Assets	(mil)	$16.47
Liability	(mil)	$17.91

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Weinberg & Company PA raised substantial doubt about GVI Security Solutions, Inc.'s ability to continue as a going concern after auditing the Company's financial statements for the year ended December 31, 2006. The auditor pointed to the Company's recurring losses and negative cash flows from operating activities, which have resulted in a negative working capital and stockholders' deficit.

Intellectual Property: The Company has several registered trademarks for "GVI" in connection with the products it sells. [SEC Filing 10-K 03-29-07]

Description: The Company provides video surveillance and security solutions to the homeland security, professional, and business-to-business markets. The Company is a primary supplier of Samsung Eletronics video surveillance products.

Officers: David Weiner (Chair); Steven E. Walin (CEO & Dir.); Joseph Restivo (CFO & Dir.); Craig Ellins (Dir.); Gary Freeman (Dir.); Moshe Zarmi (Dir.)

Auditor: Weinberg & Company PA

Securities: Common Stock Symbol GVSS.OB; OTC BB;
28,006,164 common shares outstanding as of March 23, 2007.

Return to top

Prospector Profile 07.0484

Inovio Biomedical Corporation

11494 Sorrento Valley Road
San Diego, CA 92121
(858) 597-6006

NAICS		541710
Employees		33
Revenue	(mil)	$3.47
Income	(mil)	($12.48)
Assets	(mil)	$35.95
Liability	(mil)	$14.26

(for the year ended 12/31/2006)

Category: Loss/Deficit

Event: Inovio Biomedical Corporation reported a net loss of $12,479,124 for the year ended December 31, 2006, compared to $15,296,852 in 2005 and $10,972,931 in 2004. The Company had revenues of $3,468,178 for fiscal year 2006, compared to $5,467,253 in 2005 and $1,167,099 in 2004. As a result of its recurring losses, the Company has an accumulated deficit of $128,754,730 as of December 31, 2006.

Intellectual Property: The Company maintains a broad-based patent portfolio that as of December 31, 2006, includes over 62 issued U.S. patents and 181 issued foreign counterpart patents, all of which collectively include claims to methods and/or devices for clinical use in the electroporation medical arts. Specifically, patents include method and device claims for delivering medically important substances to the interior of cells in various body tissues. The Company's core technology is centered on five broad, medically relevant "indication" categories including oncology, gene therapy/delivery, vascular administration, transdermal administration, and ex vivo administration. The Company also has a number of issued U.S. and foreign patents claiming a widely used gene regulation technology called GeneSwitch® that permits control of gene expression from DNA sequences via a small molecule that can be administered orally. In addition to electroporation technology for gene delivery, the Company also acquired a group of patents claiming the delivery of DNA using polymers and lipids that are useful in the development of certain DNA vaccines. [SEC Filing 10-K 03-16-07]

Description: The Company engages in the development and commercialization of medical therapies to address a various diseases with critical unmet treatment needs using electroporation therapy.

Officers: Avtar Dhillon (Pres., CEO & Dir.); Peter Kies (CFO); Felix Theeuwes (Dir.); Riaz Bandali (Dir.); James L. Heppell (Dir.); Simon X. Benito (Dir.); Tazdin Esmail (Dir.)

Auditor: Ernst & Young LLP

Securities: Common Stock-Symbol INO; AMEX;
38,176,204 common shares outstanding as of March 28, 2007.

Return to top

Prospector Profile 07.0485

Javelin Pharmaceuticals, Inc.
125 CambridgePark Drive
Cambridge, MA 02140
(617) 349-4500

NAICS		541710
Employees		28
Revenue	(mil)	$0.84
Income	(mil)	($17.80)
Assets	(mil)	$21.44
Liability	(mil)	$3.21

(for the year ended 12/31/2006)

Category: Loss/Deficit

Event: Javelin Pharmaceuticals, Inc. reported a net loss for the fiscal year ended December 31, 2006 of $17,798,236 on revenues of $842,171, higher than the combined net loss of the previous two years. The Company incurred a net loss of $10,611,772 on revenues of $1,547,753 in 2005 and a net loss of $7,046,828 on revenues of $836,841 in 2004. As a result of its recurring losses, the Company has an accumulated deficit of $79,438,309 as of December 31, 2006.

Intellectual Property: The Company has sought to obtain, where appropriate, the broadest intellectual property protection possible for product candidates, proprietary information and proprietary technology through a combination of contractual arrangements and patents. It currently has exclusive licenses to eight issued U.S. patents and their foreign equivalent patents and patent applications, as well as five of its own pending U.S. patent applications, each of which is also the subject of foreign equivalent applications. To help protect proprietary know-how that is not patentable, and for inventions for which patents may be difficult to enforce, the Company relies on trade secret protection and confidentiality agreements to protect its interests. The names Dyloject and Rylomine are registered trademarks in the European Union, and in the U.S., the Company has filed "intent-to-use" trademark applications for these names, both of which have been allowed. It also has pending "use-based" trademark applications in the U.S. for the name "Javelin", its logo and the name used in combination with its logo. [SEC Filing 10-K 03-16-07]

Description: The Company, together with its subsidiaries, engages in the research, development, and commercialization of products for pain relief in the United States.

Officers: Douglas G. Watson (Chair); Fred H. Mermelstein, Ph.D. (Pres. & Dir.); Daniel B. Carr, M.D. (CEO, CMO & Dir.); Stephen J. Tulipano (CFO); David B. Bernstein (Sec. & Gen. Counsel); Jackie M. Clegg (Dir.); Martin J. Driscoll (Dir.); Neil W. Flanzraich (Dir); Georg Nebgen, Ph.D. (Dir.)

Auditor: McGladrey & Pullen, LLP

Securities: Common Stock-Symbol JAV; AMEX;
40,463,081 common shares outstanding as of March 1, 2007.

Return to top

Prospector Profile 07.0486

Jordan Industries, Inc.
ArborLake Centre, 1751 Lake Cook Road
Deerfield, IL 60015
(847) 945-5591

NAICS		550000
Employees		1,393
Revenue	(mil)	$256.68
Income	(mil)	$163.40
Assets	(mil)	$311.73
Liability	(mil)	$403.28

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Ernst & Young LLP, in Chicago, expressed substantial doubt about Jordan Industries Inc.'s ability to continue as a going concern after auditing the company's financial statements for the years ended Dec. 31, 2006, and 2005. The auditing firm pointed to the company's substantial debt maturing within the next year.

Intellectual Property: The Company protects its confidential, proprietary information as trade secrets. The Company's products are generally not protected by virtue of any proprietary rights such as patents. There can be no assurance that the steps taken by the Company to protect its proprietary rights will be adequate to prevent misappropriation of its technology and know-how or that the Company's competitors will not independently develop technologies that are substantially equivalent to or superior to the Company's technology. In addition, the laws of some foreign countries do not protect the Company's proprietary rights to the same extent as do the laws of the United States. [SEC Filing 10-K 03-30-07]

Description: The Company was organized to acquire and operate a diverse group of businesses with a corporate staff providing strategic direction and support. The Company's continuing operations are comprised of four businesses, Deflecto, Sate-Lite, Beemak and GramTel.

Officers: John W. Jordan II (Chair & CEO); Thomas H. Quinn (Pres., COO & Dir.); Gordon L. Nelson (SVP & Treas.); Lisa M. Ondrula (SVP, Asst. Sec. & CFO); G. Robert Fisher (Sec. & Dir.); Steven L. Rist (Gen. Counsel & Asst. Sec.); Joseph S. Steinberg (Dir.); David W. Zalaznick (Dir.); Jesse Clyde Nichols III (Dir.)

Auditor: Ernst & Young LLP

Securities: 100,511.2249 common shares outstanding as of March 30, 2007.

Notes: The Company reported an income from discontinued operations of $175.932 million for fiscal year 2006, without which, it would have reported a net loss of $12.529 million.

Return to top

Prospector Profile 07.0487

Kosan Biosciences, Inc.
3832 Bay Center Place
Hayward, CA 94545
(510) 732-8400

NAICS		541710
Employees		82
Revenue	(mil)	$13.51
Income	(mil)	($29.47)
Assets	(mil)	$71.19
Liability	(mil)	$29.43

(for the year ended 12/31/2006)

Category: Loss/Deficit

Event: Kosan Biosciences Corporation reported a net loss of $29.469 million on revenues of $13.506 million for the fiscal year ended December 31, 2006, roughly the same as last year's loss of $29.637 million on revenues of $13.410 million. As a result of its recurring losses, the Company has an accumulated deficit of $160.306 million as of December 31, 2006.

Intellectual Property: The Company's intellectual property consists of patents, copyrights, trademarks, trade secrets and know-how. Its ability to compete effectively depends on the ability to obtain patents and trademarks for its technologies and products, maintain trade secrets, operate without infringing the rights of others and prevent others from infringing proprietary rights. As of December 31, 2006, the Company owned or exclusively licensed approximately 134 patents and 91 patent applications in the U.S. and approximately 71 foreign patents and 279 foreign patent applications. It also also relies on trade secrets to protect technology where patent protection is deemed inappropriate or unobtainable. It protects proprietary technology and processes, in part, by confidentiality agreements with employees, consultants, collaborators and certain contractors. [SEC Filing 10-K 03-16-07]

Description: The Company develops cancer therapeutics products focused on advancing two new classes of anticancer agents through clinical development: heat shock protein 90 (Hsp90) inhibitors and epothilones.

Officers: Robert G. Johnson, Jr., M.D., Ph.D. (Pres., CEO & Dir.); Robert De Jager, M.D. (SVP); Margaret A. Horn, J.D. (SVP, Sec. & Gen. Counsel); Peter J. Licari, Ph.D. (SVP); Pieter B.M.W.M. Timmermans, Ph.D. (SVP); Gary S. Titus, C.P.A. (SVP & CFO); Bruce A. Chabner, M.D. (Dir.); Kevan Clemens, Ph.D. (Dir.); Peter Davis, Ph.D. (Dir.); Jean Deleage, Ph.D. (Dir.); Charles J. Homcy, M.D. (Dir.); Chaitan S. Khosla, Ph.D. (Dir.); Christopher T. Walsh, Ph.D. (Dir.)

Auditor: Ernst & Young LLP

Securities: Common Stock-Symbol KOSN; NasdaqCM;
42,461,170 common shares outstanding as of February 28, 2007.

Return to top

Prospector Profile 07.0488

La Jolla Pharmaceutical Company

6455 Nancy Ridge Drive
San Diego, CA 92121
(858) 452-6600

NAICS		541710
Employees		84
Revenue	(mil)	$0.00
Income	(mil)	($39.45)
Assets	(mil)	$49.53
Liability	(mil)	$6.24

(for the year ended 12/31/2006)

Category: Loss/Deficit

Event: La Jolla Pharmaceutical Company reported a net loss for the year ended December 31, 2006 of $39.445 million, compared to $27.363 million in 2005 and $40.544 million in 2004. As a result of its continuing losses, the Company has an accumulated deficit of $299.757 million as of December 31, 2006.

Intellectual Property: The Company files patent applications in the United States and in foreign countries for the protection of proprietary technologies and drug candidates. It currently owns 111 issued patents and has 65 pending patent applications in the United States and in foreign countries covering various technologies and drug candidates, including lupus drug candidates, SSAO inhibitor technology, antibody-mediated thrombosis drug candidates, Tolerance Technology, and carrier platform and linkage technologies for Toleragens. [SEC Filing 10-K 03-16-07]

Description: The Company engages in the research and development of pharmaceutical products in the United States.

Officers: Deirdre Y. Gillespie, M.D. (Pres., CEO & Dir.); Matthew D. Linnik, Ph.D. (EVP & Chief Scientific Officer); Michael Tansey, M.D., Ph.D. (EVP & Chief Medical Officer); Craig R. Smith, M.D. (Dir.); Thomas H. Adams, Ph.D. (Dir.); Robert A. Fildes, Ph.D. (Dir.); Stephen M. Martin (Dir.); Nader J. Naini (Dir.); Martin Sutter (Dir.); James N. Topper, M.D., Ph.D. (Dir.); Frank E. Young, M.D., Ph.D. (Dir.)

Auditor: Ernst & Young LLP

Securities: Common Stock-Symbol LJPC; NasdaqGM;
32,712,200 common shares outstanding as of March 2, 2007.

Return to top

Prospector Profile 07.0489

Lightspace Corporation

529 Main Street, Suite 330
Boston, MA 02129
(877) 404-1700

NAICS		335122
Employees		14
Revenue	(mil)	$0.85
Income	(mil)	($2.71)
Assets	(mil)	$1.57
Liability	(mil)	$1.27

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Miller Wachman LLP raised substantial doubt about the ability of Lightspace Corporation to continue as a going concern after auditing the Company's financial statements as of Dec. 31, 2006, and 2005. The auditing firm pointed to the Company's deficiencies in stockholders' equity and recurring losses and negative cash flows from operations.

Intellectual Property: Lightspace has filed for a number of domestic and international patents covering core aspects of its technology, all of which are currently pending. The Company has received trademark protection in the United States for the mark Lightspace®. The Company also relies on copyright laws to protect computer programs relating to its Web sites and proprietary technologies, although to date it has not registered for copyright protection. The Company has registered Internet domain names related to its business in order to protect proprietary interests. It also enters into confidentiality and invention assignment agreements with employees and consultants and confidentiality agreements with other third parties, and actively monitors access to proprietary technology. [SEC Filing 10-K 03-26-07]

Description: The Company provides cutting edge interactive lighting and entertainment products to numerous industries.

Officers: Gary Florindo (Pres. & CEO); Chris Cantone (SVP-Sales); Brian Batease (VP); Tim Brown (VP)

Securities: Common Stock-Symbol LGTS.OB; OTC BB;
10,593,111 common shares outstanding as of March 21, 2007.

Return to top

Prospector Profile 07.0490

Matritech, Inc.

330 Nevada Street
Newton, MA 02460
(617) 928-0820

NAICS		325410
Employees		75
Revenue	(mil)	$12.20
Income	(mil)	($11.93)
Assets	(mil)	$5.51
Liability	(mil)	$8.30

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: PricewaterhouseCoopers LLP raised substantial doubt about the ability of Matritech, Inc. to continue as a going concern after auditing the Company's financial statements for the year ended December 31, 2006. The auditing firm pointed to the Company's recurring losses and negative cash flows from operations.

Intellectual Property: The Company has filed US patent applications and, in certain circumstances, foreign counterparts in selected other countries on developments relating to its nuclear matrix protein technology and to other cancer marker related technologies. It currently has 14 United States patents and two pending patent applications on file in the US relating to nuclear matrix proteins and current product line or programs under development. Certain of the US patents provides protection for its NMP22 Test Kit and NMP22 BladderChek Test until 2015. The Company also continues to rely on unpatented proprietary information and trade secrets. In August 2004, the Company entered into a license agreement, effective as of April 1, 2004, with Abbott Laboratories. In November 2006, the Company also executed a supply agreement with Inverness, which holds substantial patent rights in the lateral flow area covering the professional field, which includes licensed health care providers and diagnostic laboratories. [SEC Filing 10-K 03-27-06]

Description: The Company develops, manufactures, markets, distributes, and licenses cancer diagnostic technologies, products and services.

Officers: Stephen D. Chubb (Chair & CEO); David L. Corbet (Pres. & COO); Richard A. Sandberg (VP, CFO, & Treas.); Walter O. Fredericks (Dir.); Judith Kurland (Dir.); Bruce Lehman (Dir.); David B. Musket (Dir.); Jonathan M. Niloff (Dir.); Robert J. Rosenthal (Dir.); T. Stephen Thompson (Dir.); C. William Zadel (Dir.)

Auditor: PricewaterhouseCoopers LLP

Securities: Common Stock Symbol MZT; AMEX;
59,908,270 common shares outstanding as of March 13, 2007.

Return to top

Prospector Profile 07.0491

Micromet, Incorporated

2110 Rutherford Rd.
Carlsbad, CA 92008
(760) 494-4200

NAICS		541710
Employees		79
Revenue	(mil)	$27.58
Income	(mil)	($33.99)
Assets	(mil)	$51.17
Liability	(mil)	$26.65

(for the year ended 12/31/2006)

Category: Loss/Deficit

Event: Micromet, Inc. reported a net loss of $33.992 million for fiscal year 2006, much higher than the reported net loss of $19.050 million in 2005 and $25.068 million in 2004. The Company reported increased revenues of $27.583 million in fiscal year 2006, compared to $25.723 million in 2005 and $16.741 million in 2004. As a result of its recurring losses, the Company reported an accumulated deficit of $144.807 million as of December 31, 2006.

Intellectual Property: As of December 31, 2006, the Company owned or has licensed approximately 42 U.S. patents, 27 U.S. patent applications, 47 foreign and international patents, and 118 foreign and international patent applications related to its technologies, compounds, and their use for the treatment of human diseases. The number of licensed patents does not include various divisionals, continuations and continuations-in-part of the licensed patents and patent applications. The Company's issued patents in the United States expire during 2008 and 2018, and its issued patents in Europe and other jurisdictions expire in 2019. The Company has additional patent applications that, if granted, would extend patent lives significantly beyond these expirations. The Company intends to continue using scientific expertise to pursue and file patent applications on new developments with respect to products, uses, methods and compositions of matter to enhance its intellectual property position in the field of antibody therapeutics for the of treatment of human diseases. [SEC Filing 10-K 03-16-07]

Description: The Company is focused on the research, development and commercialization of novel biological products for the treatment and control of cancer.

Officers: Christian Itin (Pres., CEO & Dir.); William R. LaRue (SVP & CFO); Michael G. Carter (Dir.); Barclay A. Phillips (Dir.); Phillip M. Schneider (Dir.); Jerry Benjamin (Dir.); John Berriman (Dir.); Otello Stampacchia (Dir.); Peter Johann (Dir.)

Auditor: Ernst & Young LLP

Securities: Common Stock-Symbol MITI; NasdaqGM;
31,502,128 common shares outstanding as of March 5, 2007.

Return to top

Prospector Profile 07.0492

NexMed, Inc.
350 Corporate Boulevard
Robbinsville, NJ 08691
(609) 208-9688

NAICS		325412
Employees		18
Revenue	(mil)	$1.87
Income	(mil)	($8.04)
Assets	(mil)	$19.93
Liability	(mil)	$8.43

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Amper, Politziner & Mattia PC raised substantial doubt about the ability of NexMed, Inc. to continue as a going concern after auditing the Company's financial statements for the year ended December 31, 2006. The auditing firm pointed to the Company's recurring losses and negative cash flows from operations and its expectation for the Company to incur future losses. The Company posted a net loss of $8,043,253 on revenues of $1,866,927 for the year ended December 31, 2006, as compared with a net loss of $15,442,438 for the same period in the prior year. The Company also reported that its accumulated deficit grew to $125,730,874 at December 31, 2006, from $117,687,621 last year.

Intellectual Property: The Company has 12 U.S. patents either acquired or received out of a series of patent applications filed in connection with its NexACT® technology and NexACT-based products under development. To further strengthen its global patent position on proprietary products under development, and to expand the patent protection to other markets, the Company has filed under the Patent Cooperation Treaty, corresponding international applications for its issued U.S. patents and pending U.S. patent applications. In July 2006, the Company announced a Notice of Allowance from the U.S. Patent & Trademark Office for its U.S. patent application entitled "Prostaglandin Compositions & Methods of Treatment for Male Erectile Dysfunction." In addition, the Company has over 200 International patents and U.S. and International patent applications pending. [SEC Filing 10-K 03-26-07]

Description: The Company develops therapeutic products based on proprietary delivery systems for commercialization.

Officers: Leonard A. Oppenheim (Chair); Richard J. Berman (Pres. & CEO); Vivian H. Liu (EVP, COO, & Sec.); Mark Westgate (VP, CFO, & Treas.); Arthur D. Emil (Dir.); Sami A. Hashim (Dir.); David S. Tierney (Dir.); Martin Wade III (Dir.)

Auditor: Amper, Politziner & Mattia PC

Securities: Common Stock Symbol NEXM; NasdaqGM;
80,354,714 common shares outstanding as of March 17, 2007.

Return to top

Prospector Profile 07.0493

NextPhase Wireless, Inc.

300 South Harbor Boulevard, Suite 500
Anaheim, CA 92805
(714) 765-0010

NAICS		517212
Employees		13
Revenue	(mil)	$0.64
Income	(mil)	($1.86)
Assets	(mil)	$0.47
Liability	(mil)	$1.78

(for the year ended 3/31/2006)

Category: Loss/Deficit

Event: NextPhase Wireless, Inc.'s balance sheet at Dec. 31, 2006, showed $1,875,683 in total assets and $3,713,839 in total liabilities, resulting in a $1,838,155 stockholders' deficit. The Company's Dec. 31 balance sheet also showed strained liquidity with $254,886 in total current assets available to pay $1,394,398 in total current liabilities. For the fiscal third quarter ended Dec. 31, 2006, the Company reported a $357,472 net loss on $531,095 of revenues, compared with $326,210 of net income on $97,541 of revenues in the prior year period.

Intellectual Property: NextPhase's proprietary wireless products are based on readily available component parts, units and off-the-shelf software. The Company's technology is not patented, nor has it obtained or applied for, copyright registration for its products. The configuration and specifications of its products and the compilation, integration, bundling or embedding of component parts and software are protected as a trade secret. The Company believes that the designs, complexity and total integration of components and software in its products and know-how best protects trade secrets. [SEC Filing 10-K 07-14-06]

Description: The Company provides integrated Internet, voice, and data communications solutions primarily in California.

Officers: Stephen D. Young (Chair); Robert Ford (Pres., CEO, CFO, Treas. & Dir.); Michael Jones (Dir.)

Auditor: Russell Bedford Stefanou Mirchandani LLP

Securities: Common Stock-Symbol NXPW.OB; OTC BB;
29,948,995 common shares outstanding as of February 16, 2007.

Return to top

Prospector Profile 07.0494

Paincare Holdings, Inc.

1030 North Orange Avenue, Suite 105
Orlando, FL 32801
(407) 367-0944

NAICS		621498
Employees		573
Revenue	(mil)	$63.73
Income	(mil)	($26.48)
Assets	(mil)	$163.38
Liability	(mil)	$66.03

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: KHM PA raised substantial doubt about the ability of PainCare Holdings, Inc. to continue as a going concern after auditing the Company's financial statements for the year ended December 31, 2006. The auditing firm noted that the Company has debt obligations that are currently in default. A significant portion of the Company's assets are pledged as collateral, and foreclosure would seriously impair the Company's ability to operate.

Intellectual Property: In January 2005, the Company unveiled a new proprietary ancillary service designed to address severe knee pain and stiffness caused by osteoarthritis. The intra-articular joint program will be integrated into the service offerings provided by each suitable physician practice in its national healthcare organization. The intra- articular joint program is a proprietary, technologically advanced, non-operative knee treatment protocol that combines a five to six week series of strategically targeted injections of Hyalgan - the first FDA-approved hyaluronan therapy to treat osteoarthritis knee pain in the United States, with synergistic orthopedic rehabilitation procedures specifically designed to strengthen blood flow to the knee. [SEC Filing 10-K 04-02-07]

Description: The Company specializes in providing pain relief services through pain management technologies, minimally invasive spine surgery and orthopedic rehabilitation.

Officers: Merrill Reuter (Chair); Ronald L. Riewold (Pres. & Dir.); Randy Lubinsky (CEO & Dir.); Mark Szporka (CFO & Dir.); Jay L. Rosen (Dir.); Arthur J. Hudson (Dir.); Robert Fusco (Dir.); Aldo F. Berti (Dir.); Thomas J. Crane (Dir.)

Auditor: BKHM PA

Securities: Common Stock Symbol PRZ; AMEX;
66,679,788 common shares outstanding as of March 21, 2007.
7.5% convertible debenture due July 1, 2007

Return to top

Prospector Profile 07.0495

Point Therapeutics, Inc.

155 Federal Street
Boston, MA 02110
(617) 933-2130

NAICS		541710
Employees		40
Revenue	(mil)	$0.00
Income	(mil)	($29.37)
Assets	(mil)	$12.57
Liability	(mil)	$4.62

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Ernst & Young LLP raised doubt on Point Therapeutics, Inc.'s ability to continue as a going concern after auditing its financial statements for the year ended December 31, 2006. The Company has incurred recurring operating losses and negative cash flows from operating activities in each of the last five years and has an accumulated deficit of $91,734,000 as of December 31, 2006, and will be required to obtain additional funding or alternative means of financial support, or both, prior to December 31, 2007, in order to continue as a going concern.

Intellectual Property: In May 1997, its wholly-owned subsidiary, Point Therapeutics Massachusetts, Inc., entered into a license agreement with Tufts University School of Medicine, under which it has been granted exclusive, worldwide rights to a boroproline family of small molecule compounds, including talabostat. The license from Tufts includes 9 issued U.S. patents, 4 pending U.S. patent applications and corresponding foreign patents or patent applications in major commercial markets, including North America, Europe, and Japan. Additionally, the Company owns 8 issued U.S. patents, 12 pending U.S. patent applications and corresponding foreign patents or patent applications in the major commercial markets, including North America, Europe and Japan. [SEC Filing 10-K 03-16-07]

Description: The Company engages in the development of dipeptidyl peptidase inhibitors for use in cancer, type 2 diabetes, and as vaccine adjuvants.

Officers: Donald R. Kiepert, Jr. (Chair, Pres. & CEO); Richard N. Small (SVP, Treas. & CFO); Michael P. Duffy (SVP, Sec. & Gen. Counsel); Barry Jones, Ph.D. (SVP & Chief Scientific Officer); Margaret J. Uprichard, Pharm.D. (SVP & Chief Dev't. Officer)

Auditor: Ernst & Young LLP

Securities: Common Stock-Symbol POTP; NasdaqCM;
39,307,000 common shares outstanding as of March 9, 2007.

Return to top

Prospector Profile 07.0496

RNS Software, Inc.
2197 West 2nd Avenue, Suite 103
Vancouver, British Columbia V6K 1H7
Canada
(604) 789-2410

NAICS		511210
Employees		1
Revenue	(mil)	$0.00
Income	(mil)	($54.57)
Assets	(mil)	$37.95
Liability	(mil)	$7.98

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Dale Matheson Carr-Hilton Labonte LLP raised substantial doubt on RNS Software, Inc.'s ability to continue as a going concern. The auditor pointed out that the Company has not generated revenues since inception, has incurred losses in developing its business, and further losses are anticipated. The Company requires additional funds to meet its obligations and the costs of its operations.

Intellectual Property: Pursuant to a technology purchase agreement dated May 6, 2005, the Company acquired a 100% undivided right in and to the SEOdoctor software package, all rights, title and interest in and to the SEOdoctor domain at www.seodoctor.com, present customer database, and all intellectual property rights related to SEOdoctor products and trademarks. [SEC Filing 10-KSB 03-15-07]

Description: The Company develops and markets a search engine optimization software package named SEOdoctor.

Officers: Livio Susin (Pres., Sec., Treas. & Dir.)

Auditor: Dale Matheson Carr-Hilton Labonte LLP

Securities: Common Stock-Symbol RNSW.OB; OTC BB;
26,085,000 common shares outstanding as of March 1, 2007.

Return to top

Prospector Profile 07.0497

Siga Technologies, Inc.

420 Lexington Avenue, Suite 601
New York, NY 10170
(212) 672-9100

NAICS		541710
Employees		44
Revenue	(mil)	$7.26
Income	(mil)	($9.90)
Assets	(mil)	$14.03
Liability	(mil)	$6.75

(for the year ended 12/31/2006)

Category: Loss/Deficit

Event: Siga Technologies Inc. reported for the fiscal year ended December 31, 2006 a net loss of $9,898,708 on revenues of $7,257,532, higher than than net loss incurred last year of $2,287,550 on revenues of $8,476,741. As a result of its recurring losses, the Company has an accumulated deficit at December 31, 2006 of $56,367,619, higher than last year's accumulated deficit of $46,468,911.

Intellectual Property: The Company has licensed the rights to eight issued U.S. patents and three issued European patents. These patents have varying lives and they are related to the technology licensed from Rockefeller University for the strep and Gram-positive products. The Company has one additional patent application in the U.S. and one application in Europe relating to this technology. The Company jointly owns with Washington University seven issued patents in the U.S. and one in Europe. In addition, there are four co-owned U.S. patent applications. These patents are for the technology used for the Gram-negative product opportunities. The Company also exclusively owns two U.S. patent and two U.S. utility patent applications. One of these U.S. utility applications relates to the DegP product opportunities. It also also exclusively owns three U.S. provisional patent applications. [SEC Filing 10-K 03-16-07]

Description: The Company engages in the discovery, development, and commercialization of products for use in defense against biological warfare agents, such as smallpox and arenaviruses.

Officers: Eric A. Rose, M.D. (Chair & CEO); Thomas N. Konatich (CFO); Donald G. Drapkin (Dir.); James J. Antal (Dir.); Thomas E. Constance (Dir.); Adnan M. Mjalli, Ph.D. (Dir.); Scott Hammer, M.D. (Dir.); Paul G. Savas (Dir.); Mehmet C. Oz, M.D. (Dir.); Judy S. Slotkin (Dir.); Michael Weiner, M.D. (Dir.)

Auditor: PricewaterhouseCoopers LLP

Securities: Common Stock-Symbol SIGA; NasdaqCM;
32,674,394 common shares outstanding as of March 7, 2007.

Return to top

Prospector Profile 07.0498

SpatiaLight, Incorporated

Five Hamilton Landing, Suite 100
Novato, CA 94949
(415) 883-1693

NAICS		334419
Employees		19
Revenue	(mil)	$0.47
Income	(mil)	($18.97)
Assets	(mil)	$7.68
Liability	(mil)	$15.08

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Odenberg, Ullakko, Muranishi & Co. LLP expressed doubts on SpatiaLight, Inc.'s ability to continue as a going concern after auditing the Company's financial statements. The auditing firm noted that the Company has suffered recurring operating losses and negative cash flows from operations, and has a negative working capital position and a stockholders' deficit. As of December 31, 2006, the Company has negative net working capital of $12.9 million and an accumulated deficit of $100.6 million, with total stockholders' deficit of $7.4 million. Management believes that the Company's cash resources will not be sufficient to sustain its operations beyond March 2007 without additional financing.

Intellectual Property: The Company currently has five U.S. patents and has other U.S. and international patent applications pending. The scope of the issued patents includes physical structure design of the metal layers used for light blocking in the silicon die, several silicon die circuitry designs, and a dual panel system design. The applications are in the area of light engine level system enhancements and drive circuitry concepts. The Company also relies on unpatented proprietary technology. [SEC Filing 10-K 03-16-07]

Description: The Company develops, designs, manufactures and markets miniature high-resolution active matrix liquid crystal displays for computer, video and other applications.

Officers: David F. Hakala (Chair, CEO & COO); Michael S. Jin (Chief Tech. Officer); Claude Piaget (Dir.); Robert C. Munro (Dir.); Jerilyn Kessel (Dir.); Herbert Ehrenthal (Dir.)

Auditor: Odenberg, Ullakko, Muranishi & Co. LLP

Securities: Common Stock-Symbol HDTV; NasdaqCM;
47,773,092 common shares outstanding as of March 14, 2007.

Return to top

Prospector Profile 07.0499

SunCom Wireless Holdings, Inc.

1100 Cassatt Road
Berwyn, PA 19312
(610) 651-5900

NAICS		517212
Employees		1,924
Revenue	(mil)	$852.88
Income	(mil)	($337.38)
Assets	(mil)	$1,654.86
Liability	(mil)	$2,071.75

(for the year ended 12/31/2006)

Category: Loss/Deficit

Event: SunCom Wireless Holdings, Inc. posted a net loss of $337,378,000 on revenues of $852,879,000 for the year ended December 31, 2006, as compared with a net loss of $496,808,000 on revenues of $826,158,000 for the same period in the prior year. As of December 31, 2006, the Company's balance sheet showed its stockholders' deficit increased to $416,892,000 from $83,266,000 in the prior year and its accumulated deficit increased to $1,027,824,000 from $690,446,000 in the prior year.

Intellectual Property: The SUNCOM service mark is registered with the US Patent and Trademark Office. The following service marks containing the word SUNCOM are also registered with the US Patent and Trademark Office: SUNCOM and DESIGN; SUNCOM AT YOUR SERVICE; SUNCOM CONNECT; SUNCOM FYI; SUNCOM INET; SUNCOM KEEP TALKING; SUNCOM PREPAID TO GO; SUNCOM STATES; SUNCOM SUBSCRIPTION WIRELESS; SUNCOM SUPERSTATES; SUNCOM TO GO; SUNCOM UNLIMITED; SUNCOM UNPLAN; SUNCOM USA; SUNCOM WELCOME HOME; and SUNCOM WIRELESS and DESIGN. In addition, the following marks are registered with the US Patent and Trademark Office: M-NET; TRUE FIT; TRUTH IN WIRELESS; and WE GET IT. [SEC Filing 10-K 03-09-07]

Description: The Company provides digital wireless communications services in the southeastern U.S., Puerto Rico, and the U.S. Virgin Islands.

Officers: Michael E. Kalogris (Chair & CEO); Eric Haskell (EVP, CFO & Dir.); Harry Roessner (VP & Controller); Scott I. Anderson (Dir.); Mathias DeVito (Dir.); Arnold Sheiffer (Dir.)

Auditor: PricewaterhouseCoopers LLP

Securities: Common Stock Symbol SWSH.OB; OTC BB;
71,252,554 common shares outstanding as of February 9, 2007.

Return to top

Prospector Profile 07.0500

Taro Pharmaceutical Industries Ltd.
Italy House, Euro Park
Yakum, Israel 60972
972-9-971-1821

NAICS		325400
Revenue	(mil)	$297.74
Income	(mil)	$5.68
Assets	(mil)	$579.01
Liability	(mil)	$342.15

(for the year ended 12/31/2005)

Category: Audit Concerns

Event: Kost Forer Gabbay & Kasierer raised substantial doubt about Taro Pharmaceutical Industries Ltd.'s ability to continue as a going concern after auditing the company's financial statements as of Dec. 31, 2005, and 2004. The auditing firm pointed to the Company's substantial reduction in revenue and cash flows that adversely affected the company's current results of operations and liquidity. In addition, the Company has not compiled with certain covenants of its debt agreements.

Intellectual Property: The Company has greatly increased efforts to develop new proprietary products, including T-2000 and T2001, novel formulation of Ovide®, and products utilizing NonSpil®. The Company has filed and received patents in the United States and other countries for a variety of products, processes and methods of treatment, including: a novel class of drug with utility as anticonvulsants, tranquilizers, muscle relaxants and agents for treatment of movement disorders; novel oral delivery for pharmaceutical and related products; and the synthesis and formulation of certain products. The Company has registered trademarks in the United States, Canada and other countries. Taro U.S.A. typically does not use trademarks in the sale and marketing of its generic products. [SEC Filing 20-F03-20-07]

Description: The Company develops, manufactures, and markets high-quality generic and branded pharmaceuticals, both prescription and over-the-counter, used by patients in countries around the world.

Officers: Barrie Levitt, M.D. (Chair); Daniel Moros, M.D. (Vice Chair); Samuel Rubinstein (SVP); Avraham Yacobi, Ph.D. (SVP); Tal Levitt, Esq. (Sec. & Dir.); Myron Strober, C.P.A. (Dir.); Heather Douglas, Esq. (Dir.); Micha Friedman, Ph.D. (Dir.); Eric Johnston, Esq. (Dir.); Gad Keren, M.D. (Dir.); Ben Zion Hod, C.P.A. (Dir.); Haim Fainaro, C.P.A. (Dir.)

Auditor: Kost Forer Gabbay & Kasierer

Securities: Common Stock-Symbol TAROF.PK; PNK;
29,301,349 common shares outstanding as of December 31, 2005.

Return to top

Prospector Profile 07.0501

Visiphor Corporation

Suite 1100 – 4710 Kingsway
Burnaby, British Columbia V5H 4M2
Canada
(604) 684-2449

NAICS	541512	
Employees	55	
Revenue	CAD(mil)	$6.38
Income	CAD(mil)	($6.68)
Assets	CAD(mil)	$3.92
Liability	CAD(mil)	$4.51

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Grant Thornton LLP disclosed that the financials of Visiphor Corporation are affected by conditions and events that cast substantial doubt on Visiphor's ability to continue as a going concern. The Company incurred net losses of CAD6.7 million and CAD6.6 million in the years ended Dec. 31, 2006 and Dec. 31, 2005, respectively. The Company has never been profitable and there can be no assurance that, in the future, the company will be profitable on a quarterly or annual basis. The Company reported CAD6.4 million in total revenues for the year ended Dec. 31, 2006, as compared with CAD3.3 million in total revenues for the year ended Dec. 31, 2005.

Intellectual Property: The Company's success will depend upon its ability to protect its intellectual property rights. The Company relies principally on a combination of copyright, patent and trade secret laws, non-disclosure agreements and other contractual provisions to establish and maintain its proprietary rights. As part of its confidentiality procedures, the Company generally enters into non-disclosure and confidentiality agreements with each of its key employees, consultants, and business partners and limits access to and distribution of its technology, documentation, and other proprietary information. In addition, the Company's source code for its software products is maintained in a controlled environment within the technology and development group. [SEC Filing 10-KSB 03-23-07]

Description: The Company specializes in the development and deployment of solutions to the problem of integrating disparate business processes and databases.

Officers: Oliver "Buck" Revell (Chair); Roy Davidson Trivett (CEO & Dir.); Amin Sunil (CFO); Al Kassam (VP & Dir.); Keith Kretschmer (Dir.); Michael C. Volker (Dir.); Clyde Farnsworth (Dir.); Norman Inkster (Dir.); Wanda Dorosz (Dir.)

Auditor: Grant Thornton LLP

Securities: Common Stock-Symbol VISRF.OB; OTC BB;
44,114,775 common shares outstanding as of March 22, 2007.

Return to top

Prospector Profile 07.0502

Wave Systems Corporation

480 Pleasant Street
Lee, MA 01238
(413) 243-1600

NAICS		541511
Employees		96
Revenue	(mil)	$3.12
Income	(mil)	($18.79)
Assets	(mil)	$9.36
Liability	(mil)	$3.44

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: KPMG LLP raised substantial doubt about Wave Systems Corporation's ability to continue as a going concern after auditing the Company's financial statements. The Company has incurred substantial operating losses since its inception, and as of December 31, 2006, has an accumulated deficit of $303,532,099. As of December 31, 2006, the Company has working capital of $5,369,273.

Intellectual Property: The Company has been issued 11 US patents relating to encryption and to the proprietary EMBASSY and Wave Commerce technology. It also has 8 patents pending before the US Patent Office. In addition, it has 2 foreign patents and 29 pending foreign patent applications. The Company relies on trade secrets and proprietary know-how, which it protects, in part, by confidentiality agreements with employees and contract partners. The Company also relies on copyright law to prevent the unauthorized duplication of software and hardware products. [SEC Filing 10-K 03-16-07]

Description: The Company develops, produces, and markets products for hardware-based digital security, including security applications and services in the United States.

Officers: John E. Bagalay, Jr. (Chair); Steven K. Sprague (Pres., CEO & Dir.); Gerard T. Feeney (SVP, CFO & Sec.); George Gilder (Dir.); Nolan Bushnell (Dir.); John E. McConnaughy, Jr. (Dir.)

Auditor: KPMG LLP

Securities: Common Stock-Symbol WAVX; NasdaqGM;
42,203,773 common shares outstanding as of December 31, 2006.

Return to top